Leukemia and Lymphoma Program
Our program offers a large team of providers with specialized expertise in treating all forms of leukemia and lymphoma, including acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Hodgkin lymphoma, and non-Hodgkin lymphoma (NHL). Each year, our leukemia and lymphoma program cares for more than 150 newly diagnosed patients using a variety of treatment protocols, including bone marrow transplantation (BMT) and Phase I and II trials for patients whose cancer has relapsed or is not responding to treatment.
Our program includes:
- Physicians with national Children's Oncology Group (COG) leadership roles and expertise in ALL, AML and Hodgkin lymphoma.
- Status as one of a select group of centers offering chimeric antigen receptor (CAR T-cell therapy for relapsed leukemia, as well as ongoing research to develop new CAR T-cell technology.
- Leading a first-in-pediatrics study examining the effects of combining everolimus with other T-cell-specific chemotherapy in children with relapsed or refractory
- T-cell ALL (T-ALL) lymphoblastic lymphoma (LLy) - the goal of the study is to allow more T-ALL/LLy patients to attain remission and proceed to stem cell transplant.
Click the button for more information about our program and research.
Our leukemia and lymphoma team:
- Waitman Aumann, MD
- D. John Bergsagel, MD
- Kevin Bunting, PhD
- Sharon Castellino, MD, MSc, Program Director
- Frank Keller, MD
- Miyoung Lee, PhD
- Tamara Miller, MD, MSCE
- Melinda Pauly, MD
- Christopher Porter, MD
- Cheng-Kui Qu, MD, PhD
- Sunil Raikar, MD
- Himalee Sabnis, MD, MSc, Medical Director
- Daniel Wechsler, MD, PhD